Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome

Blood Coagulation and Fibrinolysis

Volumn 26, Issue 5, 2015, Pages 499-504

  Ghozlan, Manal F ^a   Foad, Dina A ^a   Darwish, Yasser W ^a   Saad, Abeer A ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

acute coronary syndrome; cytochrome P450 2C9; Egyptian population; Vitamin K epoxide reductase oxidaxe complex subunit 1

Indexed keywords

CYTOCHROME P450 2C9; ENZYME; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE OXIDAXE COMPLEX SUBUNIT 1; WARFARIN; ANTICOAGULANT AGENT; VITAMIN K EPOXIDE REDUCTASE; VKORC1 PROTEIN, HUMAN;

ACUTE CORONARY SYNDROME; ADULT; AGE; ALLELE; ARTICLE; CROSS-SECTIONAL STUDY; DEMOGRAPHY; EGYPTIAN; ENZYME SUBUNIT; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEIGHT; HETEROZYGOTE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; WILD TYPE; DOSE RESPONSE; ENZYMOLOGY; GENETICS; MIDDLE AGED; YOUNG ADULT;

ACUTE CORONARY SYNDROME; ADULT; ANTICOAGULANTS; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 CYP2C9; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; VITAMIN K EPOXIDE REDUCTASES; WARFARIN; YOUNG ADULT;

EID: 84941566837     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0000000000000272     Document Type: Article

References (30)

1. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, et al. On behalf of the International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753-764
2. Loebstein R, Yonath H, Peleg D, Almog S, Rotenberg M, Lubetsky A, et al. Interindividual variability in sensitivity to warfarin: nature or nurture? Clin Pharmacol Ther 2001; 70: 159-164
3. Caldwell MD, Berg RL, Zhang KQ, Glurich I, Schmelzer JR, Yale SH, et al. Evaluation of genetic factors for warfarin dose prediction. Clin Med Res 2007; 5: 8-16
4. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008; 84: 326-331
5. Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358: 999-1008
6. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009; 5: e1000433
7. Voora D, Koboldt DC, King CR, Lenzini PA, Eby CS, Porche-Sorbet R, et al. A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther 2010; 87: 445-451
8. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-Anticoagulant effect of warfarin. Blood 2005; 105: 645-649
9. Pérez-Andreu V, Roldán V, González-Conejero R, Hernández-Romero D, Vicente V, Marín F. Implications of pharmacogenetics for oral anticoagulants metabolism. Curr Drug Metab 2009; 10: 632-642
10. Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C, et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 2007; 121: 23-34
11. Seip RL, Duconge J, Ruano G. Implementing genotype-guided antithrombotic therapy. Future Cardiol 2010; 6: 409-424
12. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165: 1095-1106
13. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S, et al. The largest prospective warfarin-Treated cohort supports genetic forecasting. Blood 2009; 113: 784-792
14. Kringen MK, Haug KB, Grimholt RM, Stormo C, Narum S, Opdal MS, et al. Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction. J Biomed Biotechnol 2011; 2011: 1-5
15. Sconce EA1, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106: 2329-2333
16. Burzynski SR. Aging: gene silencing or gene activation? Med Hypotheses 2005; 64: 201-208
17. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 2009; 41: 67-76
18. Haug KB, Sharikabad MN, Kringen MK, Narum S, Sjaatil ST, Johansen PW, et al. Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction. Thromb J 2008; 6: 7
19. Tatarunas V, Lesauskait V, Veikutien A, Jakuška P, Benetis R. The influence of CYP2C9 and VKORC1 gene polymorphisms on optimal warfarin doses after heart valve replacement. Medicina (Kaunas) 2011; 47: 25-30
20. Stepien E, Branicka A, Ciesla-Dul M, Undas A. A vitamin K epoxide reductase-oxidase complex gene polymorphism (-1639GA) and interindividual variability in the dose-effect of vitamin K antagonists. J Appl Genet 2009; 50: 399-403
21. Budnitz DS, Shehab N, Kegler SR, Richards CL. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med 2007; 147: 755-765
22. Özer M, Demirci Y, Hizel C, Sarikaya S, KaraltiI , Kaspar Ç , et al. Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population. Basic Clin Pharmacol Toxicol 2013; 112: 209-214
23. Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008; 112: 1022-1027
24. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287: 1690-1698
25. Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, et al. Cytochrome P450 2C9(CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinant of acenocoumaraol sensitivity. Blood 2005; 106: 135-140
26. Borgiani P, Ciccacci C, Forte V, Romano S, Federici G, NovelliG.Allelic variants in CYP2C9 and VKORC1 loci and inter-individual variability in anticoagulant dose effect of warfarin in Italians Pharmacogenomics 2007 8 1545-1550
27. Azzam H, Elwakeel H, Awad I, El-Farahaty R, El-Gilany AH, El-Sharawy S. VKORC1 and CYP2C9 genotypes in Egyptian patients with warfarin resistance. Blood Coagul Fibrinolysis 2014; [Epub ahead of print]
28. Moyer TP, O'Kane DJ, Baudhuin LM, Wiley CL, Fortini A, Fisher PK, et al. Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. Mayo Clin Proc 2009; 84: 1079-1094
29. Shahin MH, Khalifa SI, Gong Y, Hammad LN, Sallam MT, El Shafey M, et al. Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. Pharmacogenet Genomics 2011; 21: 130-135
30. Bazan NS, Sabry NA, Rizk A, Mokhtar S, Badary OA. Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism. Ir J Med Sci 2014; 183: 161-172